The DTX3 antibody targets Deltex-3 (DTX3), a member of the Deltex family of E3 ubiquitin ligases, which play critical roles in modulating cellular signaling pathways. Initially identified as a regulator of the Notch signaling pathway, DTX3 is involved in ubiquitination processes that influence protein degradation, trafficking, and interaction networks. Structurally, DTX3 contains a conserved N-terminal Deltex domain and a C-terminal RING finger domain essential for its E3 ligase activity.
DTX3 gained attention for its role in immune regulation and cancer biology. It forms a complex with PARP9. creating a heterodimer (DTX3L-PARP9) implicated in DNA damage repair, interferon signaling, and antiviral responses. This complex is recruited to sites of DNA damage, where it facilitates ubiquitination and modulates repair mechanisms. Dysregulation of DTX3 has been linked to cancers, including lymphomas and solid tumors, where it may influence tumor progression, metastasis, and drug resistance.
Antibodies against DTX3 are vital tools for studying its expression, localization, and interaction partners in both physiological and pathological contexts. They are used in techniques like Western blotting, immunohistochemistry, and co-immunoprecipitation to explore DTX3's role in cellular processes and disease mechanisms. Research on DTX3 antibodies also contributes to potential therapeutic strategies targeting ubiquitination pathways or Notch signaling in oncology and immunology.